|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's range||198.09 - 215.11|
|52-week range||76.59 - 331.68|
|Beta (5Y monthly)||1.60|
|PE ratio (TTM)||N/A|
|Earnings date||05 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||271.75|
The correct answer to the question is Novavax (NASDAQ: NVAX). Novavax is by far the best-performing vaccine stock with a gain of more than 4,900% since the beginning of last year. Is it too late to buy Novavax stock?
To cherry-pick the data a bit, Dogecoin returned greater than 27,000% between early November and early May, when Tesla CEO Elon Musk (aka the "Dogefather") hosted Saturday Night Live and made mention of the "people's currency," Dogecoin. On July 20, you could snag a single Dogecoin for a little over $0.16, which represents a decline of approximately 78% in just over 10 weeks. Although momentum has played a big role in driving cryptocurrency prices higher, the fact remains that Dogecoin never possessed any competitive advantages.
BioNTech and Pfizer look for the vaccine to rake in sales of around $26 billion this year. BioNTech's shares are trading at a seeming bargain because investors aren't sure how much recurring revenue the company will be able to count on after 2022. If booster doses are needed going forward, BioNTech's future sales could be massive for a long time to come.